Adénocarcinome du pancréas
CHUV
I
Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC) + SOC chemotherapy + nivolumab
CHUV
To determine the feasibility, safety and tolerability of producing and administering PEP-DC vaccines in the indicated population of patients.
To evaluate immunogenicity by measuring acquired, T cell-mediated immune activating events post vaccination.